| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2015
|
11.98
|
|
2
|
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
|
Lancet
|
2008
|
10.74
|
|
3
|
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
|
J Clin Oncol
|
2013
|
5.48
|
|
4
|
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
|
J Clin Oncol
|
2012
|
4.44
|
|
5
|
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
|
Lancet Oncol
|
2012
|
4.29
|
|
6
|
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
|
J Clin Oncol
|
2009
|
4.27
|
|
7
|
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
|
J Clin Oncol
|
2006
|
3.52
|
|
8
|
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2010
|
3.13
|
|
9
|
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2011
|
2.92
|
|
10
|
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.
|
J Clin Oncol
|
2008
|
1.92
|
|
11
|
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.71
|
|
12
|
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
|
J Clin Oncol
|
2011
|
1.63
|
|
13
|
Targeted therapies for non-small cell lung cancer.
|
Lung Cancer
|
2009
|
1.63
|
|
14
|
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
|
J Clin Oncol
|
2012
|
1.55
|
|
15
|
Diagnostics and staging procedures in non-small cell lung cancer - is less more?
|
Clin Respir J
|
2008
|
1.38
|
|
16
|
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
|
J Thorac Oncol
|
2008
|
1.34
|
|
17
|
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.30
|
|
18
|
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
|
Lung Cancer
|
2009
|
1.21
|
|
19
|
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
|
Lung Cancer
|
2009
|
1.11
|
|
20
|
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
|
Clin Cancer Res
|
2008
|
1.08
|
|
21
|
Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
|
J Thorac Oncol
|
2012
|
1.07
|
|
22
|
Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).
|
J Thorac Oncol
|
2010
|
1.02
|
|
23
|
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
|
Lung Cancer
|
2011
|
1.02
|
|
24
|
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
|
J Thorac Oncol
|
2014
|
1.00
|
|
25
|
Anesthetic influence on occurrence and treatment of the trigemino-cardiac reflex: a systematic literature review.
|
Medicine (Baltimore)
|
2015
|
1.00
|
|
26
|
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
|
J Thorac Oncol
|
2015
|
0.99
|
|
27
|
First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology.
|
Eur Respir Rev
|
2014
|
0.99
|
|
28
|
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer.
|
Lung Cancer
|
2012
|
0.99
|
|
29
|
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
|
J Thorac Oncol
|
2010
|
0.98
|
|
30
|
Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2008
|
0.97
|
|
31
|
Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
|
J Thorac Oncol
|
2012
|
0.95
|
|
32
|
Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysis.
|
Respir Med
|
2012
|
0.95
|
|
33
|
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
|
Cancer
|
2014
|
0.95
|
|
34
|
Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis.
|
Respir Med
|
2010
|
0.94
|
|
35
|
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.
|
Clin Cancer Res
|
2007
|
0.94
|
|
36
|
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
|
J Thorac Oncol
|
2007
|
0.93
|
|
37
|
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
|
J Thorac Oncol
|
2013
|
0.92
|
|
38
|
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.90
|
|
39
|
Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
|
J Clin Oncol
|
2013
|
0.89
|
|
40
|
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
|
Oncol Rep
|
2012
|
0.88
|
|
41
|
A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
|
Clin Lung Cancer
|
2013
|
0.87
|
|
42
|
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
|
J Thorac Oncol
|
2015
|
0.84
|
|
43
|
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
|
Future Oncol
|
2014
|
0.84
|
|
44
|
An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.
|
Lung Cancer
|
2012
|
0.82
|
|
45
|
Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.
|
Diagn Pathol
|
2014
|
0.82
|
|
46
|
Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.
|
J Thorac Oncol
|
2012
|
0.82
|
|
47
|
Targeted therapies: Thalidomide in lung cancer therapy-what have we learned?
|
Nat Rev Clin Oncol
|
2010
|
0.81
|
|
48
|
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.
|
Oncology
|
2012
|
0.81
|
|
49
|
Characteristics, treatment patterns and outcomes of patients with small cell lung cancer--a retrospective single institution analysis.
|
Lung Cancer
|
2010
|
0.81
|
|
50
|
Efficacy and safety of bronchoscopic laser therapy in patients with tracheal and bronchial obstruction: a retrospective single institution report.
|
Clin Respir J
|
2011
|
0.81
|
|
51
|
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
|
Eur Respir J
|
2013
|
0.78
|
|
52
|
Crizotinib.
|
Recent Results Cancer Res
|
2014
|
0.78
|
|
53
|
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
|
Adv Ther
|
2010
|
0.77
|
|
54
|
Immunotherapy for Lung Cancer.
|
Oncol Res Treat
|
2016
|
0.76
|
|
55
|
Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer.
|
Expert Rev Anticancer Ther
|
2014
|
0.76
|
|
56
|
[Non-small cell lung cancer - diagnostics and stage-adapted therapy].
|
Med Klin (Munich)
|
2007
|
0.75
|
|
57
|
[Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV].
|
Onkologie
|
2006
|
0.75
|
|
58
|
[Follow-up, complications and their treatment in the surgical, radiotherapeutic and pharmacological treatment of lung cancer].
|
Onkologie
|
2011
|
0.75
|
|
59
|
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer.
|
Clin Lung Cancer
|
2006
|
0.75
|
|
60
|
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.
|
Lung Cancer
|
2013
|
0.75
|
|
61
|
Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.
|
Cancer Biomark
|
2012
|
0.75
|
|
62
|
Combinations Therapies.
|
Prog Tumor Res
|
2015
|
0.75
|
|
63
|
[Response judgement - conventional versus new methods].
|
Onkologie
|
2009
|
0.75
|
|
64
|
[Current developments and perspectives in targeted therapies].
|
Onkologie
|
2010
|
0.75
|
|
65
|
[Therapy in elderly patients].
|
Onkologie
|
2008
|
0.75
|
|
66
|
A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies.
|
Cancer Chemother Pharmacol
|
2003
|
0.75
|
|
67
|
Novel angiogenesis inhibitors in nonsmall cell lung cancer.
|
Curr Opin Oncol
|
2015
|
0.75
|